GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

TherapeuticsMD

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment. The Company previously announced the signing of a definitive agreement on March 6, 2022. TherapeuticsMD remains eligible to receive an additional $7 million

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare's financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx's offering to pharmaceutical manufacturers while helping to improve patient access and adhere

GoodRx Closes Acquisition of vitaCare, A Tech-Enabled Pharmacy Services Platform

Astronics

Atlantica Sustainable Infrastructure

Las Vegas Sands

Safeguard your portfolio by dumping these toxic stocks- Atlantica Yield (AY), Astronics (ATRO), GoodRx (GDRX) and Las Vegas Sands (LVS).

Beware of These 4 Toxic Stocks Amid Market Uncertainty

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it will release its first quarter 2022 financial results after U.S. markets close on Monday, May 9, 2022. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Prior to the call, GoodRx will issue a press release containing a li

GoodRx Announces Date for First Quarter 2022 Earnings Release and Conference Call

This Pummeled Healthcare Stock Could Come Roaring Back

Airbnb

Booking Hlds

Netflix

Spotify

This quarter's results will be the first to reflect the impact of Russia's invasion of Ukraine, as well as a sharp jump in both interest rates and fuel prices.

Netflix and Other Internet Companies Report Earnings Soon. Don't Get Your Hopes Up.

Starbucks

The Worst Is Still to Come for These 2 Crashing Stocks

Investors were not happy with the company's latest earnings results, nor with its 2022 guidance.

Why GoodRx Tanked by 29.5% in March

AMN Healthcare Services

AMN vs. GDRX: Which Stock Is the Better Value Option?

AMN or GDRX: Which Is the Better Value Stock Right Now?

AMN vs. GDRX: Which Stock Should Value Investors Buy Now?

Pharmaceutical drug savings and digital healthcare platform GoodRx (NASDAQ: GDRX) stock has falling to all-time lows accelerated by the sell-off in benchmark indexes

GoodRx Stock is a Potential Buy the Dip Opportunity

Baird analysts say the stock's valuation is more attractive after a significant selloff.

GoodRx Pullback Is 'Attractive Entry Point.' Why This Analyst Upgraded the Stock.

Trouble might be brewing on a few fronts.

3 Things About GoodRx That Smart Investors Know

The stock was trading at just under $28 before its earnings numbers were posted. Now it's down to less than $16.

Should You Buy GoodRx After Its Massive 40% Post-Earnings Crash?

GoodRx Holdings Inc (NASDAQ: GDRX) recently announced it is buying vitaCare for $150 million. These are the details.

Why GoodRx (GDRX) Is Buying vitaCare For $150 Million

Digital healthcare platform GoodRx is set to acquire vitaCare Prescription Services from TherapeuticsMD for $150 million, the company announced Monday (March 7). The vitaCare platform helps patients understand their health coverage, identify ways to save and facilitates communication between payors and providers, while also providing a path to get prescriptions filled through its network of […]

GoodRX Pays $150M for Health Platform vitaCare

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it has entered into a definitive agreement to divest its vitaCare Prescription Services (vitaCare) business to GoodRx (Nasdaq: GDRX), a consumer-focused digital healthcare platform. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications. Under the term

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it has entered into a definitive agreement to acquire vitaCare Prescription Services from TherapeuticsMD. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications. Specifically, vitaCare helps patients understand coverage and identify available savings opportunities, and facilitates commun

GoodRx Agrees to Acquire vitaCare, A Tech-Enabled Pharmacy Services Platform

Discount drug prescription site GoodRx plunged 39% after the company missed estimates on revenue and gave a weak forecast.

GoodRx shares plunge 39% after revenue miss, weak forecast

Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's Q4 FY21 earnings came in below expectations. Several analysts have downgraded the stock with reduced price targets in reaction to the earnings.

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

Prescription drug price-comparison tool GoodRx is suffering major losses today. GDRX is down big after failing to beat earnings estimates.

Is GDRX Stock a Buy After Major Plunge? 3 Analysts Weigh In on GoodRx.

GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.  GoodRx said revenue increased 39% year-over-year to $213.3 million, which came in below the $217.46 million estimate.

Why GoodRX Shares Are Plummeting Today

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates

GoodRx Holdings reported earnings on Monday (Feb. 28) that, at least as far as investors were concerned, were not good enough, even as monthly active consumer counts gained double-digit percentages. COVID-19 was a continuing headwind to growth, particularly as concerns prescriptions and refills.

GoodRx Shares Sink to Lows as COVID Pinches Prescription Transactions

Goodrx Holdings, Inc. (GDRX) CEO Doug Hirsch on Q4 2021 Results - Earnings Call Transcript

News for GoodRx Holdings Stock (GDRX)